We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > TARIS

News List

Johnson & Johnson Acquires TARIS Biomedical americanpharmaceuticalreview
January 02, 2020
Johnson & Johnson announced the acquisition of TARIS Biomedical, a privately-owned biotechnology company specializing in the development of a novel drug delivery technology ...
TARIS Initiates Clinical Trial of TAR-200, Opdivo® Combo americanpharmaceuticalreview
July 12, 2019
TARIS Bio™ announced the dosing of the first patient in a Phase 1b clinical trial evaluating the investigational product TAR-200 in combination with Opdivo® (nivolumab), a programmed death-1 (PD-1) immune checkpoint inhibitor from Bristol-Myers Squibb.
TARIS Announces Positive Results of TAR-200 Trial americanpharmaceuticalreview
June 27, 2019
TARIS Bio™ announced positive safety, tolerability and preliminary efficacy data from the full patient cohort (n=20) of its Phase 1b study of TAR-200 for the treatment of patients with muscle invasive bladder cancer (MIBC), neoadjuvant to radical cystecto
TARIS Announces Positive Topline Data for TAR-302 americanpharmaceuticalreview
August 29, 2018
TARIS announced positive preliminary safety and efficacy data from its clinical study of TAR-302 for the treatment of patients with idiopathic overactive bladder (OAB) refractory to oral therapy.